68ga-dotanoc and Ovarian-Neoplasms

Metastasis to the breast is a rare occurrence and constitutes less than 2% of all breast tumors. Similarly, ovarian metastases from neuroendocrine tumors are also uncommon, and if the adnexal masses are bilateral, then the chances of it being metastatic rather than being primary range from 88% to 94%. We present a case of 61-year-old woman who in the course of workup for abdominal pain and diarrhea was eventually diagnosed as ileal neuroendocrine tumor with breast, ovarian, and lymph nodal metastases on Ga-DOTANOC PET/CT scan.

Topics: Breast Neoplasms; Female; Humans; Ileal Neoplasms; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Probability

Bilateral ovarian metastasis from neuroendocrine tumor (NET) is uncommon. Ovarian NET could be primary or metastatic, and if it is bilateral, then the chances of metastatic disease are from 88% to 94%. Proper identification and appropriate management become necessary in such patients. Somatostatin receptor imaging by Ga-labeled DOTANOC ([1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-NaI3-Octreotide) PET/CT can be used for localization, staging, and restaging of NET, and it also has an impact on appropriate clinical management of patients with NET. We present here a case of somatostatin receptor expressing bilateral ovarian metastases from NET demonstrated by Ga DOTANOC PET/CT imaging.

Topics: Female; Humans; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed

The management of neuroendocrine tumours is challenging when curative surgery is ruled out because of distant metastases. We report a case of gastrointestinal carcinoid with bilateral ovarian metastases in a 50-year-old female who received octreotide therapy followed by peptide receptor radionuclide therapy and surgery thereafter. Somatostatin receptor expression on neuroendocrine tumours has implications in diagnosis and therapy. (68)Ga-DOTA-NOC PET is a recent advancement in the field of somatostatin receptor imaging. The lesions which demonstrate tracer uptake on positron emission tomographic studies can be further planned for treatment with octreotide and (177)Lu-DOTA-TATE. The case in discussion responded well to non-invasive treatment options before proceeding to definitive surgical management.

Topics: Antineoplastic Agents; Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Middle Aged; Octreotide; Organometallic Compounds; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin